Fujifilm Diosynth Biotechnologies U.S.A. has opened up a new biomanufacturing site in America’s CRO heartland as the company looks to boost its biologics offering.
The CDMO--which works on recombinant biopharmaceuticals including proteins, vaccines, and monoclonal antibodies--completed the construction of a new three-story, 62,000-square-foot, state-of-the-art facility in Research Triangle Park, NC earlier this week.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO of the subsidiary of Japanese parent company Fujifilm Holdings Corporation.
The new building, called “BioProcess Innovation Center,” houses the company’s process and analytical research and development, process sciences and stability groups.
These will concentrate on delivering excellence in process invention, design and development and process and product characterization for the CDMO’s clients. They will also continue to innovate to further develop systems and approaches which lead to more efficient, robust and high quality biomanufacturing processes.
“The design of the facility reflects our core philosophy of cross-functional collaboration to research and process development which is a key differentiator of our company,” its president Martin Meeson, added.
“Developer Alexandria Real Estate Equities, Inc., and General Contractor, KBR Building Group, LLC, brought a wealth of experience in life science building projects to this new addition to Fujifilm Diosynth Biotechnologies--located at 6051 George Watts Hill Drive.”
- check out the release
Image of ribbon-cutting ceremony courtesy of Business Wire